OKYO — OKYO Pharma Limited

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: GB
• Exchange: NASDAQ
• Employees: 3
• Website: https://www.okyopharma.com

Latest SEC filings for OKYO

• 6-K — 2026-10-06
• 6-K — 2026-09-29
• 6-K — 2026-09-09
• 6-K — 2026-09-08
• 6-K — 2026-07-28
• 6-K — 2026-07-27
• 6-K — 2026-07-23
• 6-K — 2026-07-23
• 6-K — 2026-07-22
• 6-K — 2026-07-22

Latest OKYO news

• 2026-10-06 — OKYO Pharma enrolls first patients in Phase 3 trial of neuropathic corneal pain drug (proactiveinvestors.com)
• 2026-10-06 — OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain (globenewswire.com)
• 2026-09-29 — OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences (globenewswire.com)

Abrir análisis completo

Educational tool only — not investment advice.